TY - JOUR AU - Woyach, J A; Ruppert, A S; Heerema, N A TI - Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202 JO - Blood VL - 132 PY - 2018 DO - 10.1182/blood-2018-99-116653 SP - 6 N1 - et al. ER -